Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates

Sutro Biopharma Stock Price Forecast. Should You Buy STRO?

Sutro Biopharma (NasdaqGM:STRO) Stock Forecast & Analyst Predictions

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

Sutro Biopharma Doses First Patient In Its Phase 1 Trial Of STRO-006 In Patients With Range Of Solid Tumors; Initial Clinical Data Expected In H2 2027

Sutro's second antibody-linked cancer drug entered human testing in less than a year.

Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

STRO Stock Plummets 15% — What Drove The Selloff?

Sutro Biopharma, Inc. Common Stock (STRO) Stock Price: Oct 30 Close $9.10

STRO Forecast — Price Target — Prediction for 2027

US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results